ESZOPICLONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H17ClN6O3
Molecular Weight	388.808
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCN(CC1)C(=O)O[C@@H]2N(C(=O)C3=C2N=CC=N3)C4=CC=C(Cl)C=N4

InChI

InChIKey=GBBSUAFBMRNDJC-INIZCTEOSA-N

InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H17ClN6O3
Molecular Weight	388.808
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00402
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/eszopiclone.html

Eszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Eszopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor. The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes. Used for the treatment of insomnia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
GABA-A receptor; anion channel 202 Target ID: CHEMBL2093872 Sources: http://www.genome.jp/dbget-bin/www_bget?D02624	Agonist 2678
GABA receptor alpha-1 subunit 19 Target ID: CHEMBL1962 Sources: http://www.genome.jp/dbget-bin/www_bget?D02624	Agonist 2678	50.1 nM [Ki]
GABA receptor alpha-2 subunit 7 Target ID: CHEMBL4956 Sources: http://www.genome.jp/dbget-bin/www_bget?D02624	Agonist 2678	114.0 nM [Ki]
GABA receptor alpha-4 subunit 2 Target ID: CHEMBL2472 Sources: http://www.genome.jp/dbget-bin/www_bget?D02624	Agonist 2678	102.0 nM [Ki]
GABA receptor alpha-3 subunit 6 Target ID: CHEMBL3026 Sources: http://www.genome.jp/dbget-bin/www_bget?D02624	Agonist 2678	162.0 nM [Ki]
Translocator protein 13 Target ID: CHEMBL5742 Sources: http://www.drugbank.ca/drugs/DB00402	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 108 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	Primary		Approved 8429	LUNESTA Approved Use LUNESTA is indicated for the treatment of insomnia. Launch Date 2004

C_max

Value	Dose	Analyte	Population
19.88 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
40.28 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.15 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
25.48 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
26.18 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	3 mg 1 times / day multiple, oral dose: 3 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
54.68 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
59.63 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.29 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.58 ng/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
166.21 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
338.26 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
54.76 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
187.76 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
191.07 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	3 mg 1 times / day multiple, oral dose: 3 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
379.04 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
409.31 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
62.96 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
66.05 ng × h/mL REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	1 mg 1 times / day multiple, oral dose: 1 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.7 h REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf	2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered:		ESZOPICLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
44.45% REVIEW https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-lunivia_en.pdf			ESZOPICLONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
6 mg single, oral Highest studied dose Dose: 6 mg Route: oral Route: single Dose: 6 mg Sources: https://pubmed.ncbi.nlm.nih.gov/23038043 Page: p.564	healthy, 25–38 n = 12 Health Status: healthy Age Group: 25–38 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/23038043 Page: p.564	Sources: https://pubmed.ncbi.nlm.nih.gov/23038043 Page: p.564
3 mg 1 times / day multiple, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23038043 Page: p.564	healthy, 25–40 n = 8 Health Status: healthy Age Group: 25–40 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/23038043 Page: p.564	Sources: https://pubmed.ncbi.nlm.nih.gov/23038043 Page: p.564
90 mg single, oral Overdose Dose: 90 mg Route: oral Route: single Dose: 90 mg Sources: https://pubmed.ncbi.nlm.nih.gov/17606111	healthy, 86 n = 1 Health Status: healthy Age Group: 86 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/17606111	Disc. AE: Coma... AEs leading to discontinuation/dose reduction: Coma Sources: https://pubmed.ncbi.nlm.nih.gov/17606111
270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf Page: p.13	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf Page: p.13	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf Page: p.13
3 mg 1 times / day multiple, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Insomnia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf Page: p.1	Disc. AE: CNS depression, Alertness decreased... AEs leading to discontinuation/dose reduction: CNS depression Alertness decreased Coordination impaired Anaphylactic reaction (severe) Anaphylactoid reaction (severe) Angioedema Anaphylaxis Abnormal thinking Abnormal behaviour NOS Hallucinations Abnormal behaviour NOS Depression worsened Suicidal ideation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf Page: p.1
2 mg 1 times / day steady, oral (max) Dose: 2 mg, 1 times / day Route: oral Route: steady Dose: 2 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00856973	unhealthy n = 163 Health Status: unhealthy Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia Population Size: 163 Sources: https://clinicaltrials.gov/ct2/show/NCT00856973	Other AEs: Dysgeusia, Dizziness... Other AEs: Dysgeusia (below serious, 8 patients) Dizziness (below serious, 6 patients) Somnolence (below serious, 4 patients) Abdominal pain upper (below serious, 6 patients) Vomiting (below serious, 10 patients) Abdominal discomfort (below serious, 4 patients) Toothache (below serious, 4 patients) Upper respiratory tract infection (below serious, 13 patients) Nasopharyngitis (below serious, 9 patients) Oropharyngeal pain (below serious, 6 patients) Irritability (below serious, 4 patients) Nasal congestion (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00856973
3 mg 1 times / day steady, oral Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00374556	unhealthy n = 14 Health Status: unhealthy Condition: Osteoarthritis Population Size: 14 Sources: https://clinicaltrials.gov/ct2/show/NCT00374556	Other AEs: Restlessness... Other AEs: Restlessness (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00374556
3 mg 1 times / day steady, oral Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00645944	unhealthy n = 19 Health Status: unhealthy Condition: Schizophrenia Population Size: 19 Sources: https://clinicaltrials.gov/ct2/show/NCT00645944	Other AEs: Fatigue, Drowsiness... Other AEs: Fatigue (serious, 1 patient) Drowsiness (below serious, 8 patients) Weakness (below serious, 2 patients) Irritability (below serious, 2 patients) Headache (below serious, 4 patients) Nervousness (below serious, 1 patient) Malaise (below serious, 3 patients) Delusions (below serious, 1 patient) Dizziness (below serious, 2 patients) Vision blurred (below serious, 1 patient) Nasal congestion (below serious, 2 patients) Dry mouth (below serious, 5 patients) Bad taste (below serious, 7 patients) Tremor (below serious, 1 patient) Ataxia (below serious, 1 patient) Nausea and vomiting (below serious, 2 patients) Abdominal discomfort (below serious, 1 patient) Diarrhea (below serious, 1 patient) Sweating (below serious, 1 patient) Decreased appetite (below serious, 1 patient) Increased appetite (below serious, 2 patients) Weight loss (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00645944
3 mg 1 times / day steady, oral (max) Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00856973	unhealthy n = 159 Health Status: unhealthy Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia Population Size: 159 Sources: https://clinicaltrials.gov/ct2/show/NCT00856973	Other AEs: Sedation, Respiratory distress... Other AEs: Sedation (serious, 1 patient) Respiratory distress (serious, 1 patient) Headache (below serious, 22 patients) Dysgeusia (below serious, 22 patients) Dizziness (below serious, 13 patients) Somnolence (below serious, 6 patients) Abdominal pain upper (below serious, 8 patients) Vomiting (below serious, 5 patients) Nausea (below serious, 7 patients) Abdominal discomfort (below serious, 8 patients) Toothache (below serious, 2 patients) Urinary tract infection (below serious, 4 patients) Pyrexia (below serious, 8 patients) Nasal congestion (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00856973

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	inhibitor 1767 inducer 389	inhibitor 1852 inducer 97

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882	CYP2E1 667	CYP1A2 701 CYP2A6 79 CYP2C19 293 CYP2E1 128

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2A6 739	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2E1 970	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22;147	no	unlikely (co-administration study) Comment: 5% decrease in AUC when paroxetine was the substrate and esopiclone the interacting drug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22;147
CYP2D6 1891	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22;147	no	unlikely Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22;147

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	likely
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0	yes		yes (co-administration study) Comment: Coadministration with ketoconazole resulted in a 2.2-fold increase in exposure to eszopiclone Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021476_Lunesta_biopharmr.PDF#page=22 Page: 22.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:53760	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:53760
ChemicalBook	CB1468825	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1468825
ZINC	ZINC000019632834	http://zinc15.docking.org/substances/ZINC000019632834
eMolecules	2728749	https://www.emolecules.com/cgi-bin/more?vid=2728749

PubMed

Title	Date	PubMed
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.	2007 Feb 15	17557453
Prolonged coma after eszopiclone overdose.	2007 Jul	17606111

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Insomnia Initial dose: 1 mg orally immediately before bedtime Maintenance dose: 1 to 3 mg orally immediately before bedtime Maximum dose: 3 mg orally immediately before bedtime

Route of Administration: Oral

In Vitro Use Guide

10 uM Eszopiclone increased the mean amplitude of the IGV-induced outward current from 19.7 ± 3.9 pA to 47.1 ± 7.8 pA (n = 10) and increased duration from 396.5 ± 24.0 s to 568.8 ± 40.5 s in rat pedunculopontine neurons.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:55:44 GMT 2023` Edited by `admin` on `Fri Dec 15 15:55:44 GMT 2023`
Record UNII	UZX80K71OE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ESZOPICLONE

Official Name

English

ESZOPICLONE [USAN]

Common Name

English

Eszopiclone [WHO-DD]

Common Name

English

1-PIPERAZINECARBOXYLIC ACID, 4-METHYL-, (5S)-6-(5-CHLORO-2-PYRIDINYL)-6,7-DIHYDRO-7-OXO-5H-PYRROLO(3,4-B)PYRAZIN-5-YL ESTER

Common Name

English

ESZOPICLONE [JAN]

Common Name

English

(+)-(5S)-6-(5-CHLOROPYRIDIN-2-YL)-7-OXO-6,7-DIHYDRO-5H-PYRROLO(3,4-B)PYRAZIN-5-YL 4-METHYLPIPERAZINE-1-CARBOXYLATE

Systematic Name

English

ESZOPICLONE [VANDF]

Common Name

English

ESZOPICLONE CIV [USP-RS]

Common Name

English

LUNESTA

Brand Name

English

ESZOPICLONE [MART.]

Common Name

English

GSK-1755165

Code

English

ZOPICLONE S-FORM [MI]

Common Name

English

ESZOPICLONE [USP MONOGRAPH]

Common Name

English

ESZOPICLONE [HSDB]

Common Name

English

ZOPICLONE S-FORM

Common Name

English

ESZOPICLON

Common Name

English

ESZOPICLONE [ORANGE BOOK]

Common Name

English

ESZOPICLONE CIV

Common Name

English

eszopiclone [INN]

Common Name

English

(S)-ZOPICLONE

Common Name

English

ESTORRA

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29756